Physician profile
Myra A Reed
NPI 1215996434
$15,896.31
in general payments reported to CMS, 2019-2025
15 companies · $3,014 in 2025
The $3,014 reported for 2025 was more than what 96% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,764 · 2020: $211 · 2021: $1,871 · 2022: $1,889 · 2023: $2,088 · 2024: $2,060 · 2025: $3,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $6,653 · Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $6,653.29 |
| Food and Beverage | $508.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $14,252.88 | 2019-2025 | Ngage, Physio-Stim |
| Novo Nordisk INC | $582.54 | 2020-2025 | Ozempic, Rybelsus |
| Galderma Laboratories, L.P. | $411.82 | 2019-2023 | |
| Lilly USA, LLC | $199.92 | 2020-2024 | Zepbound |
| Allergan, INC. | $109.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.07 | 2023-2025 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $67.15 | 2023-2025 | Tirosint, Flector, Licart |
| Currax Pharmaceuticals LLC | $30.69 | 2020-2025 | Contrave |
| Astrazeneca Pharmaceuticals LP | $25.53 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $24.65 | 2024 | Dificid |
| Alexion Pharmaceuticals, INC. | $23.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.42 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.53 | 2019 | |
| Abbvie INC. | $17.72 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.